Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Rudwaleit M, Navarro-Compán V, Deodhar A, Dubreuil M, Morup MF, Taieb V, de la Loge C, Fleurinck C, Massow U, Vaux T, Boonen A (2023)
In: Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology, 75(Suppl. 9). Hoboken: Wiley: 1020-1023.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Rudwaleit, MartinUniBi;
Navarro-Compán, Victoria;
Deodhar, Atul;
Dubreuil, Maureen;
Morup, Michael Frank;
Taieb, Vanessa;
de la Loge, Christine;
Fleurinck, Carmen;
Massow, Ute;
Vaux, Thomas;
Boonen, Annelies
Einrichtung
Erscheinungsjahr
2023
Titel des Konferenzbandes
Abstract Supplement ACR Convergence 2023
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
75
Ausgabe
Suppl. 9
Seite(n)
1020-1023
Konferenz
ACR Convergence 2023
Konferenzort
San Diego, CA
Konferenzdatum
2023-11-10 – 2023-11-15
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2993457
Zitieren
Rudwaleit M, Navarro-Compán V, Deodhar A, et al. Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies. In: Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology. Vol 75. Hoboken: Wiley; 2023: 1020-1023.
Rudwaleit, M., Navarro-Compán, V., Deodhar, A., Dubreuil, M., Morup, M. F., Taieb, V., de la Loge, C., et al. (2023). Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies. Abstract Supplement ACR Convergence 2023, Arthritis & Rheumatology, 75, 1020-1023. Hoboken: Wiley. https://doi.org/10.1002/art.42700
Rudwaleit, Martin, Navarro-Compán, Victoria, Deodhar, Atul, Dubreuil, Maureen, Morup, Michael Frank, Taieb, Vanessa, de la Loge, Christine, et al. 2023. “Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies”. In Abstract Supplement ACR Convergence 2023, 75:1020-1023. Arthritis & Rheumatology. Hoboken: Wiley.
Rudwaleit, M., Navarro-Compán, V., Deodhar, A., Dubreuil, M., Morup, M. F., Taieb, V., de la Loge, C., Fleurinck, C., Massow, U., Vaux, T., et al. (2023). “Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies” in Abstract Supplement ACR Convergence 2023 Arthritis & Rheumatology, vol. 75, (Hoboken: Wiley), 1020-1023.
Rudwaleit, M., et al., 2023. Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies. In Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology. no.75 Hoboken: Wiley, pp. 1020-1023.
M. Rudwaleit, et al., “Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies”, Abstract Supplement ACR Convergence 2023, Arthritis & Rheumatology, vol. 75, Hoboken: Wiley, 2023, pp.1020-1023.
Rudwaleit, M., Navarro-Compán, V., Deodhar, A., Dubreuil, M., Morup, M.F., Taieb, V., de la Loge, C., Fleurinck, C., Massow, U., Vaux, T., Boonen, A.: Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies. Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology. 75, p. 1020-1023. Wiley, Hoboken (2023).
Rudwaleit, Martin, Navarro-Compán, Victoria, Deodhar, Atul, Dubreuil, Maureen, Morup, Michael Frank, Taieb, Vanessa, de la Loge, Christine, Fleurinck, Carmen, Massow, Ute, Vaux, Thomas, and Boonen, Annelies. “Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies”. Abstract Supplement ACR Convergence 2023. Hoboken: Wiley, 2023.Vol. 75. Arthritis & Rheumatology. 1020-1023.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar